滔搏(6110.HK)首日上市漲8.82% 市值超過百麗私有化市值
格隆匯10月10日丨百麗國際旗下的運動業務板塊滔搏(6110.HK)今日首日上市收漲8.82%,報9.25港元,成交25.33億港元,市值573.61億港元。而2017年5月,鼎暉聯手高瓴收購併私有化百麗,當時估值為531億港元。目前,滔博市值已超過百麗私有化市值。自2006年成為百麗旗下的子公司後,滔搏國際一直獨立運營。靠着賣阿迪、耐克等國際品牌,滔搏坐上了國內頭號運動品零售商的寶座。截至2019年2月28日,其在268座城市共有8343家直營門店和1880家下游零售商經營的加盟店,堪稱國內運動品“巨無霸”。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.